Neurizon Therapeutics Ltd. reported that the first participant has been enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial for amyotrophic lateral sclerosis. The company said the regimen is a 36-week randomized, double-blind, placebo-controlled adaptive Phase 2/3 study expected to enroll about 160 ALS participants across U.S. clinical sites, with participants randomized 3:1 to daily NUZ-001 at 10 mg/kg or placebo, followed by a 36-week active treatment extension. Neurizon also cited results from its Phase 1 program in 12 people with ALS, stating NUZ-001 was safe and well-tolerated and showed preliminary signals of efficacy, and said enrollment is expected to complete in the second half of calendar year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602261534PR_NEWS_USPR_____CN96616) on February 26, 2026, and is solely responsible for the information contained therein.